Johnson & Johnson (JNJ) Payables (2009 - 2026)
Johnson & Johnson (JNJ) posted Payables of $20.9 billion for Q2 2026, down 25.09% sequentially from $27.9 billion in Q1 2026, and little changed YoY from $21.0 billion in Q2 2025.
Johnson & Johnson (JNJ) Payables (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Payables for 18 years, with the latest figure at $20.9 billion in Q2 2026.
- Quarterly Payables changed 0.36% year-over-year to $20.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.9 billion (changed 0.36% YoY) and the FY2025 annual result came in at $20.5 billion, up 25.73% from the prior year.
- Payables eased to $20.9 billion in Q2 2026 per JNJ's latest filing, from $27.9 billion in the prior quarter.
- Over five years, Payables peaked at $27.9 billion in Q1 2026 and troughed at $12.2 billion in Q4 2023.
- A 5-year average of $18.4 billion and a median of $16.7 billion in 2024 frame the typical range for Payables.
- The widest YoY moves for Payables: up 104.97% in 2023, down 42.23% in 2023.
- Over 5 years, Payables stood at $14.6 billion in 2022, then slipped by 10.25% to $13.1 billion in 2023, then rose by 24.54% to $16.3 billion in 2024, then gained by 25.73% to $20.5 billion in 2025, then climbed by 2.09% to $20.9 billion in 2026.
- According to Business Quant data, Payables over the past three periods registered $20.9 billion, $27.9 billion, and $20.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 20.92 Bn |
| Mar 29, 2026 | 27.92 Bn |
| Dec 28, 2025 | 20.49 Bn |
| Sep 28, 2025 | 16.01 Bn |
| Jun 29, 2025 | 20.99 Bn |
| Mar 30, 2025 | 23.44 Bn |
| Dec 29, 2024 | 16.29 Bn |
| Sep 29, 2024 | 13.42 Bn |
| Jun 30, 2024 | 18.70 Bn |
| Mar 31, 2024 | 16.72 Bn |
| Dec 31, 2023 | 13.08 Bn |
| Oct 1, 2023 | 12.23 Bn |
| Jul 2, 2023 | 22.14 Bn |
| Apr 2, 2023 | 27.89 Bn |
| Jan 1, 2023 | 22.65 Bn |
| Oct 2, 2022 | 14.58 Bn |
| Jul 3, 2022 | 14.07 Bn |
| Apr 3, 2022 | 13.61 Bn |
| Jan 2, 2022 | 14.82 Bn |
| Oct 3, 2021 | 12.76 Bn |